The literature has reported that BRAF mutated colon cancer patients had a much poorer survival rate that wild-type patients (Phipps et al., 2015; Matos and Jordan, 2018; Taieb et al., 2019), we therefore analyzed overall survival in the two cohorts. This evidence concerns the gene BRAF and colonic neoplasm.